According to the current trends in the biotech industry and M&A logic: supplementing pipelines, addressing patent cliffs, and acquiring high-quality assets, the following lists some biotech companies with potential for acquisition. These companies typically have clinical-stage blockbuster assets, unique technology platforms, or high-value intellectual property in core areas such as oncology, autoimmune diseases, neuroscience, rare diseases, etc., with relatively reasonable valuations. I. Potential acquisition targets in the field of oncology· $Arvinas(ARVN.US) Highlights: Leader in PROTAC protein degradation technology platform...